News & Press Releases Swedish

Scandinavian ChemoTech fortsätter att satsa på Animal Care i USA och laddar för en av årets viktigaste mässor

Bolagets VD planerar att genomföra en 10 dagars turné i USA och inkluderar att aktivt delta i VMX (Veterinary Meeting and Expo), en av årets viktigaste mässor för veterinärmedicin in USA.

Read more

Scandinavian ChemoTech erhåller godkännande från amerikanska patentverket

Scandinavian ChemoTech AB meddelar idag att Bolaget har erhållit godkännande från det amerikanska patentverket för sin innovation för behandling av smärta orsakad av metastaser i ryggrad och skelett. Denna innovation är också tillämplig för behandling av djupt sittande tumörer, som är ytterligare ett av Bolagets utvecklingsprojekt.  

Read more

Scandinavian ChemoTech når kliniska framgångar inom dotterbolaget Vetiqure AB

Efter att den behandlande veterinären vid Evidensia Specialistdjursjukhuset Helsingborg genomfört sista uppföljningen av den hund som behandlades under hösten 2021 kan ett mycket gott kliniskt resultat konstateras.

Read more

News & Press Releases English

Scandinavian ChemoTech continues its focus on Animal Care in the US and prepares for one of the most important trade fairs

The company's CEO plans to conduct a 10-day tour in the United States including being present during the VMX (Veterinary Meeting and Expo), one of the most important trade fairs for veterinary medicine in the United States.

Read more

Scandinavian ChemoTech receives approval from the US Patent Office

Scandinavian ChemoTech AB announces today that the Company has received approval from the US Patent Office for its innovation for the treatment of pain caused by metastases in the spine and skeleton. This innovation is also applicable to the treatment of deep-seated tumours, which is another of the Company's development projects.

Read more

Scandinavian ChemoTech achieves clinical success within the subsidiary Vetiqure AB

After the treating veterinarian at Evidensia Specialist Animal Hospital Helsingborg carried out the last follow-up of the dog that was treated in the autumn of 2021, a very good clinical result can be confirmed.

Read more

ChemoTech Videos

Presentation of Q3 - Analysera med oss November 2021 (Swedish)

Innovative TSE technology increases the local effect of chemotherapy (Swedish)

ChemoTech presents for its upcoming Annual General meeting 24 May 2021. Spoken language is Swedish but the presentation is in English.

ChemoTech answers questions from the shareholders; Part 1 (Swedish)

CEO Mohan Frick presenting at Erik Penser Bank Bolagsdag (Swedish)

Erik Penser Bank interview with CEO Mohan Frick (Swedish) 8 January 2021

Company Presentation of the Q3 report (Swedish) 11th of November 2020

Company Presentation (Swedish) 27th of October 2020

Videos from 2019

Share Day in Gothenburg, November 4 2019 (Swedish)

Videos from 2018

Share analysis ChemoTech Q2 2018 (Swedish)

Share Day in Malmö on May 22, 2018 (Swedish)

Our foundation

Our profound knowledge in Electroporation forms the starting point for the company’s existing product and R&D projects : IQwave™ specially desinged for both TSE- Tumour Specific Electroporation and the first generation electrochemotherapy for the treatment of a range of different types of tumours.

Our research focus

Our aim is to document the effects of elctrochemotherapy for pain management for cancer patients, an area with significant unmet medical need.